Erratum to: Histo-biological comparative analysis of bilateral breast cancer(Med Oncol (2013) 30 (711) 10.1007/s12032-013-0711-8);Histo-biological comparative analysis of bilateral breast cancer

Medical Oncology

Volumn 30, Issue 4, 2013, Pages 758-

  Baker, Bilal ^a   Morcos, Basem ^a   Daoud, Faiez ^a   Sughayyer, Maher ^a   Shabani, Hisham ^a   Salameh, Habeeb ^a   Almasri, Mahmoud ^a  

^a KING HUSSEIN CANCER CENTER   (Jordan)

Author keywords

Bilateral breast cancer; Histopathological concordance; Metachronous tumor; Second primary; Synchronous tumor

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; BILATERAL CANCER; BREAST CANCER; COMPARATIVE STUDY; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; METACHRONOUS TUMOR; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECOND CANCER; SYNCHRONOUS TUMOR; BREAST TUMOR; CELL DIFFERENTIATION; MULTIPLE CANCER; PATHOLOGY; PHYSIOLOGY;

BREAST NEOPLASMS; CELL DIFFERENTIATION; FEMALE; HUMANS; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES;

EID: 84886866103     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0758-6     Document Type: Erratum

References (33)

1. Healey EA, Cook EF, Orav EJ, Schnitt SJ, Connolly JL, Harris JR. Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol. 1993;11:1545-52. (Pubitemid 23228261)
2. Beinart G, Gonzalez-Angulo AM, Broglio K, et al. Clinical course of 771 patients with bilateral breast cancer: characteristics associated with overall and recurrence-free survival. Clin Breast Cancer. 2007;7(11):867-74.
3. Khairy GA, Guraya SY, Ahmed ME, Ahmed MA. Bilateral breast cancer. Incidence, diagnosis and histological patterns. Saudi Med J. 2005;26(4):612-5. (Pubitemid 40711449)
4. Hankey BF, Curtis RE, Naughton MD, et al. A retrospective cohort analysis of second breast cancer risk for primary breast cancer patients with an assessment of the effect of radiation therapy. J Natl Cancer Inst. 1983;70(5):797-804. (Pubitemid 13101475)
5. Cook LS, White E, Schwartz SM, et al. A population-based study of contralateral breast cancer following a first primary breast cancer (Washington, United States). Cancer Causes Control. 1996;7(3):382-90. (Pubitemid 26164750)
6. Horn PL, Thompson WD. Risk of contralateral breast cancer: associations with factors related to initial breast cancer. Am J Epidemiol. 1988;128(2):309-23.
7. Dixon JM, Anderson TJ, Page DL, et al. Infiltrating lobular carcinoma of the breast: an evaluation of the incidence and consequence of bilateral disease. Br J Surg. 1983;70(9):513-6. (Pubitemid 13001788)
8. Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935-82. Natl Cancer Inst Monogr. 1985;68:99-112. (Pubitemid 16233726)
9. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310-6.
10. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995;56(1):265-71.
11. Healey EA, Cook EF, Orav EJ, et al. Contralateral breast cancer: clinical characteristics and impact on prognosis. J Clin Oncol. 1993;11(8):1545-52. (Pubitemid 23228261)
12. Engin K. Prognostic factors in bilateral breast cancer. Neoplasma. 1994;41(6):353-7.
13. Shen Y, Dong W, Esteva FJ, et al. Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center? Breast Cancer Res Treat. 2007;102(3):347-56. (Pubitemid 46474842)
14. Schaapveld M, Visser O, Louwman WJ, et al. The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat. 2008;110(1):189-97. (Pubitemid 351793865)
15. Verkooijen HM, Chatelain V, Fioretta G, et al. Survival after bilateral breast cancer: results from a population-based study. Breast Cancer Res Treat. 2007;105(3):347-57. (Pubitemid 47596444)
16. Graham MD, Yelland A, Peacock J, et al. Bilateral carcinoma of the breast. Eur J Surg Oncol. 1993;19(3):259-64. (Pubitemid 23215440)
17. Gogas J, Markopoulos C, Skandalakis P, Gogas H. Bilateral breast cancer. Am Surg. 1993;59(11):733-5. (Pubitemid 23320098)
18. Heron DE, Komarnicky LT, Hyslop T, et al. Bilateral breast carcinoma: risk factors and outcomes for patients with synchronous and metachronous disease. Cancer. 2000;88(12):2739-50. (Pubitemid 30417934)
19. Kollias J, Ellis IO, Elston CW, Blamey RW. Clinical and histological predictors of contralateral breast cancer. Eur J Surg Oncol. 1999;25(6):584-9.
20. Chaudary MA, Millis RR, Hoskins EO, et al. Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg. 1984;71(9):711-4. (Pubitemid 14066682)
21. Tse GM, Kung FY, Chan AB, et al. Clonal analysis of bilateral mammary carcinomas by clinical evaluation and partial allelotyping. Am J Clin Pathol. 2003;120(2):168-74. (Pubitemid 37046349)
22. Suspitsin EN, Sokolenko AP, Togo AV, et al. Nonrandom distribution of oncogene amplifications in bilateral breast carcinomas: possible role of host factors and survival bias. Int J Cancer. 2007;120(2):297-302. (Pubitemid 44956839)
23. Imyanitov EN, Suspitsin EN, Grigoriev MY, et al. Concordance of allelic imbalance profiles in synchronous and metachronous bilateral breast carcinomas. Int J Cancer. 2002;100(5):557-64. (Pubitemid 34816156)
24. Park SC, Hwang UK, Ahn SH, et al. Genetic changes in bilateral breast cancer by comparative genomic hybridisation. Clin Exp Med. 2007;7(1):1-5. (Pubitemid 46475009)
25. Carmichael AR, Bendall S, Lockerbie L, et al. The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. Eur J Surg Oncol. 2002;28(4):388-91.
26. Intra M, Rotmensz N, Viale G, et al. Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. Cancer. 2004;101(5):905-12. (Pubitemid 39100421)
27. Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102(3):170-8.
28. Barreau B, de Mascarel I, Feuga C, et al. Mammography of ductal carcinoma in situ of the breast: review of 909 cases with radiographic-pathologic correlations. Eur J Radiol. 2005;54(1):55-61. (Pubitemid 40417472)
29. Kollias J, Ellis IO, Elston CW, Blamey RW. Prognostic significance of synchronous and metachronous bilateral breast cancer. World J Surg. 2001;25(9):1117-24. (Pubitemid 32845821)
30. Coradini D, Oriana S, Mariani L, et al. Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour? Eur J Cancer. 1998;34(6):825-30. (Pubitemid 28248492)
31. Gong SJ, Rha SY, Jeung HC, et al. Bilateral breast cancer: differential diagnosis using histological and biological parameters. Jpn J Clin Oncol. 2007;37(7):487-92. (Pubitemid 47335466)
32. Marpeau O, Ancel PY, Antoine M, et al. Synchronous bilateral breast cancer: risk factors, diagnosis, histology and treatment. Gynecol Obstet Fertil. 2008;36(1):35-44. (Pubitemid 351200457)
33. Saad RS, Denning KL, Finkelstein SD, et al. Diagnostic and prognostic utility of molecular markers in synchronous bilateral breast carcinoma. Mod Pathol. 2008;21(10):1200-7.